EFG Capital International’s AbbVie ABBV Stock Holding History

EFG Capital International’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.38M	Buy	+10,231	New	+$1.5M	0.32%	86

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

EFG Capital International's ABBV Position: Q2 2023 in Review

EFG Capital International opened a new position in AbbVie (ABBV) in Q2 2023: 10,231 shares worth $1.38M. The stake represents 0.32% of the portfolio and ranks #86 among its holdings.

3,079 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

EFG Capital International held 10,231 shares of AbbVie worth $1.38M as of Q2 2023.
AbbVie was a new EFG Capital International position in Q2 2023.
AbbVie made up 0.32% of EFG Capital International's portfolio in Q2 2023, its #86 holding.
3,079 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.